[Heparin-induced thrombocytopenia (HIT). Problems and their significance for ENT medicine].
Kleinschmidt
S
S
Klinik für Anaesthesiologie und Intensivmedizin, Universitätskliniken des Saarlandes, Homburg/Saar.
Mertzlufft
F
F
Bach
F
F
Plinkert
P K
PK
D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D010038:Otorhinolaryngologic Diseases / Q000601:surgery; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy; D013923:Thromboembolism / Q000139:chemically induced / Q000188:drug therapy
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid